SAN ANTONIO– Hera Biotech, a leader in non-invasive diagnostic tools for women’s health, has announced the acquisition of HeraFem®, a groundbreaking point-of-care device for cervical cancer detection. The move signals a major expansion of the company’s capabilities beyond its original focus on endometriosis, addressing a critical gap in women’s health diagnostics worldwide.
Developed by Hera Diagnostics, HeraFem is designed to streamline and revolutionize cervical cancer detection. The device combines electrical and optical spectroscopy with artificial intelligence to deliver same-visit diagnostic results with 91% sensitivity for detecting CIN2+ lesions, a significant improvement over the 55–80% sensitivity range typically seen with traditional Pap tests.
“For too long, time-consuming, imprecise testing methods have shaped women’s health,” said Somer Baburek, CEO of Hera Biotech. “HeraFem eliminates location barriers, reduces misdiagnoses, and delivers the clarity women deserve—from rural Mississippi to remote Guatemala and beyond—with scientific precision and diagnostic equity.”
The timing is critical. Cervical cancer remains a leading cause of death among women globally, claiming 350,000 lives each year—94% of them in low- and middle-income countries. In the United States alone, the disease drives approximately $2.8 billion in annual healthcare costs, much of it stemming from diagnostic delays and inefficiencies in current screening protocols.
Unlike traditional testing, HeraFem requires no sample collection, sidestepping the discomfort and anxiety associated with conventional methods such as Pap smears and biopsies. It eliminates the need for cold chain transport and minimizes variables such as body mass index and sample quality, offering a more equitable and accessible diagnostic approach.
“The combination of HeraFem’s cutting-edge technology with Hera Biotech’s platform opens up a new era in women’s health,” said Teo Tijerina, CEO of Hera Diagnostics. “This integration enables fast, affordable, and precise care on a global scale.”
Hera Biotech has already secured distribution partners and pre-orders across Central and South America, with U.S. regulatory processes underway. The company is currently raising a bridge round to support commercial scaling and global distribution efforts.
As demand for accurate, point-of-care solutions grows in the $12 billion cervical cancer screening market, Hera Biotech’s latest acquisition positions it at the forefront of a new generation of women’s health diagnostics—offering precision, speed, and dignity in care for women worldwide.
